Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology

San Diego, CA, December 22, 2025 — Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript describing the discovery and preclinical characterization of small molecules that activate KEAP1 via a novel covalent allosteric molecular glue mechanism to drive degradation […] The post Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology appeared first on Vividion Therapeutics .